Citations

Showing 10 of 108081 citations.

SUDEP
Buchhalter, Jeffrey , Cascino, Gregory D.

Mayo Clinic

Neurology | June 8, 2017 | Volume: 89 | Issue: 2 | Pages: 114-115

10.1212/wnl.0000000000004099 | PMID 28592449 Get It

Pilot Feasibility Study of a Digital Storytelling Intervention for Immigrant and Refugee Adults With Diabetes
Wieland, Mark L. , Njeru, Jane W. , Hanza, Marcelo M., Boehm, Deborah H., Yawn, Barbara P. , Clark, Matthew M. , Weis, Jennifer A., Goodson, Miriam, Capetillo, Maria D. Porraz, Hared, Abdullah, Hasley, Rachel, Guzman-Corrales, Laura , Sandler, Rachel, Hernandez, Valentina, Novotny, Paul J. , Sloan, Jeff A. , Sia, Irene G. , Patten, Christi A. , Porraz Capetillo, Maria D, Singh, Davinder , Osman, Ahmed , Wieland, Mark L , Sia, Irene G

Mayo Clinic

The Diabetes Educator | June 8, 2017 | Volume: 43 | Issue: 4 | Pages: 349-359

10.1177/0145721717713317 | PMID 28592205 Get It

Purpose The purpose of this pilot feasibility project was to examine the potential effectiveness of a digital storytelling intervention designed through a community-based participatory research (CBPR) approach for immigrants and refugees with type 2 diabetes mellitus (T2DM). Methods The intervention was a 12-minute culturally and linguistically tailored video consisting of an introduction, 4 stories, and a concluding educational message. A structured interview was used to assess the intervention for acceptability, interest level, and usefulness among 25 participants with T2DM (15 Latino, 10 Somali) across 5 primary care clinical sites. After watching the video, participants rated their confidence and motivation about managing T2DM as a result of the intervention. Baseline A1C and follow-up values (up to 6 months) were abstracted from medical records. Results All participants reported that the intervention got their attention, was interesting, and was useful; 96% reported that they were more confident about managing their T2DM than before they watched the video, and 92% reported that the video motivated them to change a specific behavior related to T2DM self-management. The mean baseline A1C level for the intervention participants was 9.3% (78 mmol/mol). The change from baseline to first follow-up A1C level was −0.8% (−10 mmol/mol) ( P < .05). Conclusions Implementation of a digital storytelling intervention for T2DM among immigrant populations in primary care settings is feasible and resulted in self-rated improvement in psychosocial constructs that are associated with healthy T2DM self-management behaviors, and there was some evidence of improvement in glycemic control. A large-scale efficacy trial of the intervention is warranted.
Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final Results
Andersson, Michael , López-Vega, José Manuel, Petit, Thierry , Zamagni, Claudio , Easton, Valerie, Kamber, Julia, Restuccia, Eleonora , Perez, Edith A.

Mayo Clinic

The Oncologist | June 8, 2017 | Volume: 22 | Issue: 10 | Pages: 1160-1168

10.1634/theoncologist.2017-0079 | PMID 28592618 Get It

Abstract Background VELVET Cohort 1 demonstrated the applicability of pertuzumab, trastuzumab, and vinorelbine as an alternative first-line treatment regimen for patients with HER2-positive locally advanced or metastatic breast cancer (MBC) who cannot receive docetaxel. Co-infusion of pertuzumab and trastuzumab may reduce clinic time and medical resource utilization. We report results from Cohort 2, in which pertuzumab and trastuzumab were co-infused, followed by vinorelbine. Patients and Methods During cycle 1, patients with HER2-positive locally advanced or MBC received loading doses of pertuzumab (840 mg) and trastuzumab (8 mg/kg) on consecutive days, followed by vinorelbine (25 mg/m2) on days two and nine. From cycle 2 onwards, patients received a co-infusion of pertuzumab (420 mg) and trastuzumab (6 mg/kg) on day one, followed by vinorelbine (30–35 mg/m2) on days one and eight (or days two and nine). The primary endpoint was objective response rate (ORR) in patients with measurable disease. Secondary endpoints included progression-free survival (PFS) and safety. Results Cohort 2 enrolled 107 patients. The ORR was 63.7% (95% confidence interval [CI] 53.0–73.6) in patients with measurable disease (91/107; 85.0%). Median PFS was 11.5 months (95% CI 10.3–15.8). The most common adverse events [AEs] were diarrhea (57.9%), neutropenia (57.0%), and nausea (41.1%). Grade ≥3 AEs occurred in 85 patients (79.4%) and serious AEs in 44 patients (41.1%). Eighteen patients (16.8%) had AEs suggestive of congestive heart failure. Conclusion These results support the feasibility of pertuzumab and trastuzumab co-infusion from a safety perspective and support Cohort 1 conclusions that vinorelbine offers an alternative chemotherapy companion for pertuzumab and trastuzumab. The Oncologist 2017;22:1160–1168
Cognition in epilepsy patients with hypothalamic hamartomas
Wagner, Kathrin , Wethe, Jennifer V. , Schulze‐Bonhage, Andreas , Trippel, M., Rekate, Harold L. , Prigatano, George P. , Kerrigan, John , Schulze-Bonhage, Andreas , Wethe, Jennifer V

Mayo Clinic

Epilepsia | June 7, 2017 | Volume: 58 | Issue: S2 | Pages: 85-93

10.1111/epi.13759 | PMID 28591483 Get It

SummaryMany patients with epilepsy caused by hypothalamic hamartomas (HHs) have cognitive impairments during the course of the disease or following neurosurgical treatment. The purpose of this study was to assess cognitive function in these patients, as well as factors influencing preoperative cognitive performance and cognitive outcome after neurosurgical treatment. Using the two largest and most detailed neuropsychology datasets on HH and epilepsy from two centers, we retrospectively report on cognitive functions in 48 patients with structural epilepsy due to HH (mean age ± standard deviation [SD] 20 ± 12 years, range 5–53 years, median 16 years; disease duration mean 17 ± 11 years). Intelligence, verbal learning and recall, and speed and executive functions (processing speed and cognitive flexibility) were assessed before and on average 19 (±11) months after surgery (interstitial radiosurgery: N = 22; neurosurgical resection/disconnection: N = 26). Prior to neurosurgical treatment, 52% of patients showed impaired executive and 62% showed reduced verbal memory functions. A trend for a detrimental effect of higher drug load on cognitive functioning was found. After neurosurgical treatment, intellectual functions for the entire cohort tended to increase. This correlated with improved seizure frequency and decreased number of antiepileptic drugs (AEDs). However, postoperative outcomes for individual patients were highly variable, with significant deteriorations in 17% (processing speed) to 34% (cognitive flexibility and verbal learning), and performance increases in 17% (intellectual functioning) up to 39% (processing speed) of the patients. Higher levels of presurgical performance were significant predictors of cognitive decline after surgery. These results are highly relevant for patient consultation and may help with therapeutic decisions.
Adverse childhood or adult experiences and risk of bilateral oophorectomy: a population-based case–control study
Rocca, Liliana Gazzuola , Grossardt, Brandon R. , Shuster, Lynne T., Rocca, Walter A. , Gazzuola Rocca, Liliana, Smith, Carin Y. , Rocca, Walter A , Faubion, Stephanie S. , Stewart, Elizabeth A. , Grossardt, Brandon R

Mayo Clinic

BMJ Open | June 7, 2017 | Volume: 7 | Issue: 5 | Pages: e016045

10.1136/bmjopen-2017-016045 | PMID 28592582 Get It

Objectives Bilateral oophorectomy has commonly been performed in conjunction with hysterectomy even in women without a clear ovarian indication; however, oophorectomy may have long-term deleterious consequences. To better understand this surgical practice from the woman’s perspective, we studied the possible association of adverse childhood or adult experiences with the subsequent occurrence of bilateral oophorectomy. Design Population-based case–control study. Setting Olmsted County, Minnesota (USA). Participants From an established population-based cohort study, we sampled 128 women who underwent bilateral oophorectomy before age 46 years for a non-cancerous condition in 1988–2007 (cases) and 128 age-matched controls (±1 year). Methods Information about adverse experiences was abstracted from the medical records dating back to age 15 years or earlier archived in the Rochester Epidemiology Project (REP) records-linkage system. Adverse childhood experiences were summarised using the Adverse Childhood Experience (ACE) score. Results We observed an association of bilateral oophorectomy performed before age 46 years with verbal or emotional abuse, physical abuse, any abuse, substance abuse in the household, and with an ACE score ≥1 experienced before age 19 years (OR=3.23; 95% CI 1.73 to 6.02; p<0.001). In women who underwent the oophorectomy before age 40 years, we also observed a strong association with physical abuse experienced during adulthood (OR=4.33; 95% CI 1.23 to 15.21; p=0.02). Several of the associations were higher in women who underwent oophorectomy at a younger age (<40 years) and in women without an ovarian indication for the surgery. None of the psychosocial or medical variables explored as potential confounders or intervening variables changed the results noticeably. Conclusions Women who suffered adverse childhood experiences or adult abuse are at increased risk of undergoing bilateral oophorectomy before menopause. We suggest that the association may be explained by a series of biological, emotional, and psychodynamic mechanisms.
CHECKMATE 647: A PHASE 2, OPEN‐LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA
Nayak, Lakshmi , Ferreri, Andrés J.M. , Batlevi, Connie Lee , Batchelor, Tracy T. , Rubenstein, James L. , Johnston, Patrick B. , Ramchandren, Radhakrishnan , Soussain, Carole , Becker, Kevin, Illerhaus, Gerald , Herrera, Alex F. , Masood, Aisha, IWAMOTO, FABIO MASSAITI , Santoro, Armando , Singer, Samuel , Drappatz, Jan , Witzens‐Harig, Mathias , Shipp, Margaret Ann

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 420-421

10.1002/hon.2440_2 Get It

PHASE II STUDY OF DURVALUMAB (ANTI–PD‐L1) COMBINED WITH EITHER R‐CHOP OR LENALIDOMIDE AND R‐CHOP IN PREVIOUSLY UNTREATED, HIGH‐RISK DIFFUSE LARGE B‐CELL LYMPHOMA
Jaeger, Ulrich, Kalakonda, Nagesh , Everaus, Hele, Jaeger, Jonathan, Manzke, Oliver, Nowakowski, Grzegorz S. , Fustier, Pierre

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 419-420

10.1002/hon.2440_1 Get It

ROBUST: PHASE III RANDOMIZED STUDY OF LENALIDOMIDE/R‐CHOP VS PLACEBO/R‐CHOP IN UNTREATED ABC‐TYPE DIFFUSE LARGE B‐CELL LYMPHOMA AND FEASIBILITY OF CELL OF ORIGIN SUBTYPING
Gascoyne, Randy D. , Russo, Jacqueline, Amoroso, Barbara, Hudak, Krista, Ogunkanmi, A., Xu, Yinyan , Ruiz, Wanda, Singh, Shailesh , Nowakowski, Grzegorz S. , Chiappella, Annalisa , Witzig, Thomas E. , Vitolo, Umberto , Singh, S.

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 419-419

10.1002/hon.2440 Get It

PHASE I/II STUDY OF CHOEP PLUS LENALIDOMIDE AS INITIAL THERAPY FOR PATIENTS WITH STAGE II‐IV PERIPHERAL T‐CELL NON‐HODGKIN LYMPHOMA: PHASE I RESULTS FROM THE T‐CELL CONSORTIUM
Lunning, M., Mehta–Shah, Neha , Moskowitz, Alison J. , Beaven, Anne , Haverkos, Bradley M. , Lechowicz, MaryJo, Oki, Yasuhiro , Ansell, Stephen M. , Lunning, Matthew A. , Horwitz, Steven M. , Advani, Ranjana H. , Zain, Jasmine

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 411-412

10.1002/hon.2439_190 Get It